JP2022517109A5 - - Google Patents

Info

Publication number
JP2022517109A5
JP2022517109A5 JP2021540533A JP2021540533A JP2022517109A5 JP 2022517109 A5 JP2022517109 A5 JP 2022517109A5 JP 2021540533 A JP2021540533 A JP 2021540533A JP 2021540533 A JP2021540533 A JP 2021540533A JP 2022517109 A5 JP2022517109 A5 JP 2022517109A5
Authority
JP
Japan
Prior art keywords
independently
cancer
cancers
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021540533A
Other languages
English (en)
Japanese (ja)
Other versions
JP7335341B2 (ja
JP2022517109A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/013264 external-priority patent/WO2020150115A1/en
Publication of JP2022517109A publication Critical patent/JP2022517109A/ja
Publication of JP2022517109A5 publication Critical patent/JP2022517109A5/ja
Application granted granted Critical
Publication of JP7335341B2 publication Critical patent/JP7335341B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021540533A 2019-01-14 2020-01-13 Nlrp3モジュレーター Active JP7335341B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962791979P 2019-01-14 2019-01-14
US62/791,979 2019-01-14
PCT/US2020/013264 WO2020150115A1 (en) 2019-01-14 2020-01-13 Nlrp3 modulators

Publications (3)

Publication Number Publication Date
JP2022517109A JP2022517109A (ja) 2022-03-04
JP2022517109A5 true JP2022517109A5 (cg-RX-API-DMAC7.html) 2022-09-05
JP7335341B2 JP7335341B2 (ja) 2023-08-29

Family

ID=69469246

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540533A Active JP7335341B2 (ja) 2019-01-14 2020-01-13 Nlrp3モジュレーター

Country Status (6)

Country Link
US (1) US12391675B2 (cg-RX-API-DMAC7.html)
EP (1) EP3911641A1 (cg-RX-API-DMAC7.html)
JP (1) JP7335341B2 (cg-RX-API-DMAC7.html)
KR (1) KR102865929B1 (cg-RX-API-DMAC7.html)
CN (1) CN113286786A (cg-RX-API-DMAC7.html)
WO (1) WO2020150115A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3911642B1 (en) 2019-01-14 2026-06-10 Innate Tumor Immunity, Inc. Nlrp3 modulators
KR20240055035A (ko) * 2021-08-31 2024-04-26 니뽄 다바코 산교 가부시키가이샤 6-아미노피라졸로피리미딘 화합물 및 그 의약 용도
CN115282280A (zh) * 2022-08-12 2022-11-04 中国科学技术大学 TGF-β1信号抑制剂的新用途
EP4671246A1 (en) * 2023-02-24 2025-12-31 Japan Tobacco Inc. COMPOSITE OF 6-ALCOXYPYRAZOLOPYRIMIDINE AND ITS PHARMACEUTICAL USE
TW202448887A (zh) * 2023-02-24 2024-12-16 日商日本煙草產業股份有限公司 取代吡唑并嘧啶化合物及其醫藥用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
JP2014518267A (ja) 2011-06-27 2014-07-28 杏林製薬株式会社 細菌感染症の治療のための架橋二環式化合物
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
EP3402255B1 (en) 2016-02-02 2021-03-31 Huawei Technologies Co., Ltd. Emission power verification method, user equipment, and base station
EP3445761A1 (en) * 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
TWI674261B (zh) * 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
ES3002968T3 (en) * 2017-07-14 2025-03-10 Innate Tumor Immunity Inc Nlrp3 modulators
EP3911642B1 (en) * 2019-01-14 2026-06-10 Innate Tumor Immunity, Inc. Nlrp3 modulators
KR102815870B1 (ko) * 2019-01-14 2025-05-30 인네이트 튜머 이뮤니티, 인코포레이티드 암의 치료에 사용하기 위한 헤테로시클릭 nlrp3 조정제

Similar Documents

Publication Publication Date Title
JP2021534168A5 (cg-RX-API-DMAC7.html)
JP2021522249A5 (cg-RX-API-DMAC7.html)
JP2021534158A5 (cg-RX-API-DMAC7.html)
JP7274450B2 (ja) 癌を処置するための医薬組合せ
ES2290199T3 (es) Mezcla que incluye un agente que reduce la actividad de fcve y un agente que reduce la actividad de fce.
JP6404242B2 (ja) がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用
JP2025024006A5 (cg-RX-API-DMAC7.html)
JP2018510191A5 (cg-RX-API-DMAC7.html)
KR20210075992A (ko) Sting 작동 화합물
WO2019136298A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
JP2022517110A5 (cg-RX-API-DMAC7.html)
ES2653990T3 (es) Benzodiazepinas para tratamiento del cáncer de pulmón de células pequeñas
JP2016523974A5 (cg-RX-API-DMAC7.html)
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
RU2020113749A (ru) Аналоги таиланстатина
JP2023506787A5 (cg-RX-API-DMAC7.html)
MX2013008749A (es) Agente terapeutico o profilactico para caquexia.
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
JP2002544231A (ja) ガンを治療するための組成物とet743の使用
EP4447973A1 (en) Use of combination therapy for treating cancer
EP3996749A1 (en) Peptide conjugates of microtubule-targeting agents as therapeutics
RU2013143520A (ru) Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
JP2024542633A5 (cg-RX-API-DMAC7.html)
RU2334517C2 (ru) Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство
PT1885187E (pt) Métodos para o tratamento de cancro resistente a fármacos